Illumina

Illumina

Develops sequencing platforms and consumables

Staff Bioinformatics Scientist - DNA/RNA Secondary Analysis Algorithms

Full-TimeUpdated on 9/22/2026
$155.6k - $233.4k/yr

+ Bonus or commission + Equity

Senior, Expert
Bachelor's, Master's, PhD
Remote in USA+1 more

More locations: San Diego, CA, USA

Remote
No H1B Sponsorship

About the job

Requirements
  • A degree in Bioinformatics, Computational Biology, Computer Science, Statistics, Biology, or a related discipline, or equivalent industry experience.
  • Significant experience developing DNA/RNA bioinformatics algorithms, analytical methods, and production software for next-generation sequencing applications, such as genome alignment, transcript expression, RNA fusion and splice-variant calling, and DNA small-variant, structural-variant, and copy-number-variant calling.
  • A strong background in genomics, transcriptomics, and biological data analysis.
  • Proficiency in one or more programming languages such as C++, Python, or similar.
  • Experience designing, validating, benchmarking, and interpreting computational methods for complex biological datasets.
  • Demonstrated technical leadership and the ability to independently drive complex projects from concept to product delivery.
  • Strong communication and collaboration skills, with the ability to influence cross-functional teams and technical strategy.
  • A track record of innovation through publications, patents, invention disclosures, open-source contributions, or commercial product development.
Responsibilities
  • Lead development of novel algorithms and analytical methods for RNA and multiomic sequencing applications.
  • Design, evaluate, and implement scalable bioinformatics algorithms and methods for bulk RNA sequencing, single-cell sequencing, CRISPR/Perturb-seq analysis, ATAC-seq, CROP-seq, and emerging multiomic assays.
  • Apply machine learning, artificial-intelligence methods, foundation models, large-language-model-enabled workflows, and biological foundation models to accelerate method development, validation, interpretation, and product innovation.
  • Develop production-quality software solutions in collaboration with bioinformatics scientists, software engineers, field-programmable gate array engineers, assay development teams, and product teams.
  • Lead technical projects, define requirements, influence product direction, evaluate risks, and drive innovation across multiple product cycles.
  • Mentor scientists and engineers and contribute to scientific and technical leadership within the organization.
  • Evaluate emerging technologies and identify opportunities for new features, products, analytical capabilities, and intellectual property.
Desired Qualifications
  • At least 8 years of related experience with a Bachelor's degree, 6 years with a Master's degree, or 3 years with a PhD, or equivalent experience.
  • Experience with bulk RNA sequencing, gene expression analysis, alternative splicing, gene fusion detection, and RNA biomarker development.
  • Experience applying machine learning, artificial intelligence, or modern data science techniques to biological data analysis, method development, or software validation.
  • Experience with single-cell genomics and transcriptomics workflows.
  • Experience with CRISPR/Perturb-seq analysis, CROP-seq, ATAC-seq, spatial transcriptomics, or other multiomic assays.
  • Experience using artificial-intelligence-assisted software development and scientific analysis tools to accelerate method development, testing, validation, or interpretation.
  • Experience with cloud computing, distributed computing, or large-scale genomic data processing.
  • Knowledge of oncology, clinical genomics, population genomics, translational research, or biotechnology product development.

About the company

Illumina provides integrated sequencing platforms and related consumables for analyzing genetic variation and biological function. Its instruments range from high-throughput NovaSeq systems to benchtop MiSeq/iSeq units, all built on sequencing-by-synthesis technology acquired from Solexa. Revenue comes from instrument sales plus a recurring stream of consumables, reagents, library preparation kits, and services. The company differentiates itself with a broad end-to-end ecosystem and strategic acquisitions (Solexa, GRAIL, SomaLogic) that expand capabilities into multiomics and clinical diagnostics.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1998

Get referred to Illumina

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Illumina raised 2026 revenue guidance to $4.60 billion-$4.64 billion after Q2 strength.
  • S&P 500 inclusion on September 21, 2026 should drive passive-fund buying.
  • Clinical volume reached 78% NovaSeq X conversion, supporting recurring consumables growth.

What critics are saying

  • FTC and Fifth Circuit GRAIL litigation still threatens forced divestiture and management distraction.
  • Research consumables declined in 2026 while clinical demand carried growth, exposing narrow dependence.
  • BGI and Thermo Fisher keep pressuring sequencing pricing, risking margin compression by 2027.

What makes Illumina unique

  • NovaSeq X drives clinical sequencing workflows, with 95 placements in Q2 2026.
  • Illumina pairs sequencing, DRAGEN software, and multiomics tools into one platform.
  • The new WGS MRD research solution broadens Illumina beyond core sequencing instruments.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

-2%
Yahoo Finance
Sep 9th, 2026
Illumina joins S&P 500 on 21 September following 112% stock surge

Illumina will join the S&P 500 index on 21 September, alongside Bloom Energy and Everpure, replacing Molson Coors Beverage, The Trade Desk, and Builders FirstSource. S&P Dow Jones Indices announced the rebalancing on Friday. The San Diego-based genetic sequencing company, valued at $33 billion, has returned 112% over the past 12 months. The inclusion will trigger buying from passive funds tracking the index. Illumina is moving from the S&P MidCap 400, signalling its growth into large-cap status. In the second quarter, the company reported revenue of $1.16 billion, up 9.5% year-over-year, with earnings per share rising approximately 10% to $1.31.

Yahoo Finance
Aug 26th, 2026
Illumina beats Q2 expectations with $1.16B revenue, raises full-year guidance

Illumina reported second-quarter revenues of $1.16 billion, marking a 9.4% year-on-year increase that exceeded analyst expectations by 2.5%. The DNA sequencing and microarray technology company delivered strong organic revenue performance and raised its full-year earnings guidance. Chief executive Jacob Thaysen attributed the results to growing momentum in sequencing-intensive applications among clinical customers. The company increased its revenue and earnings guidance for the year based on this performance. Illumina's shares rose 10% following the earnings announcement and currently trade at $225.55. The results came as part of a strong second quarter for the life sciences tools and services sector overall, with the 20 tracked stocks in the group beating revenue estimates by 2.6% on average.

GenomeWeb
Aug 14th, 2026
Illumina secures $1B credit facility with Bank of America, launches note offering

Illumina has entered into a $1 billion credit facility with Bank of America serving as administrative agent. The genomics company announced the agreement after market close on Thursday. The credit facility also includes an underwriting agreement for a note offering, though specific terms were not disclosed in the announcement.

AktienSensor
Aug 12th, 2026
Illumina raises $750M with 2029 senior notes to refinance debt and lower cost of capital

Illumina has filed to issue senior notes maturing in 2029, expecting to raise approximately $750 million. The unsecured notes will rank equally with the company's other unsecured debt and feature a yield near the current US Treasury benchmark. Proceeds will primarily repay an earlier 4.65% note due in September 2026. By extinguishing higher-cost debt, Illumina aims to reduce its interest burden and improve its debt-to-equity ratio. The company expects its weighted average cost of capital to decrease from 5.8% to an estimated 4.9%. The notes include a make-whole redemption clause and a change-of-control provision requiring Illumina to purchase notes at 101% of principal plus interest. Illumina holds Moody's A-3 and S&P A- credit ratings. The refinancing supports ongoing investment in next-generation sequencing platforms, data analytics, and cloud-based services whilst enhancing financial flexibility for strategic acquisitions and R&D funding.

PR Newswire
Jul 30th, 2026
Illumina raises 2026 guidance on strong Q2 results: $1.16B revenue, up 9.5%

Illumina reported second quarter 2026 revenue of $1.16 billion, up 9.5% from the prior year period. The San Diego-based genomics company posted GAAP diluted earnings per share of $1.35 and non-GAAP diluted earnings per share of $1.31. Chief executive Jacob Thaysen said momentum built through the first half of 2026 as the company's technology enabled clinical customers to expand sequencing-intensive applications. He noted that demand for NovaSeq X remains high. Based on this performance, Illumina raised its full-year 2026 revenue guidance to $4.60-$4.64 billion, up from prior guidance of $4.52-$4.62 billion. The company increased its non-GAAP diluted earnings per share guidance to $5.30-$5.40, versus prior guidance of $5.15-$5.30.